Financial Performance - The company's operating revenue for 2023 was approximately ¥9.19 billion, representing a 17.49% increase compared to ¥7.82 billion in 2022[22]. - The net profit attributable to shareholders decreased by 42.01% to ¥133.06 million from ¥229.43 million in the previous year[22]. - The net profit after deducting non-recurring gains and losses also fell by 42.34% to ¥126.88 million from ¥220.04 million in 2022[22]. - The basic earnings per share dropped to ¥0.33, a decrease of 42.11% from ¥0.57 in the previous year[22]. - The total assets of the company increased by 18.70% to approximately ¥9.33 billion compared to ¥7.86 billion at the end of 2022[22]. - The net assets attributable to shareholders rose by 2.72% to approximately ¥2.29 billion from ¥2.23 billion in 2022[22]. - The net cash flow from operating activities was approximately ¥142.91 million, a decrease of 3.73% from ¥148.44 million in the previous year[22]. - The weighted average return on net assets decreased to 6.28%, down from 11.55% in 2022, reflecting a decline of 5.27%[22]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥0.5 per 10 shares to all shareholders, with no bonus shares issued[4]. - The profit distribution plan for 2023 proposed a cash dividend of 0.5 CNY per 10 shares (including tax), with a total cash dividend payout of 46,614,100.00 CNY[184]. - The company maintained a cash dividend policy with a clear distribution standard and procedure, ensuring the protection of shareholders' interests[185]. - The company did not issue any bonus shares or increase capital from the capital reserve during the profit distribution[184]. Market Position and Growth - The retail market for pharmaceuticals in China reached CNY 501.5 billion in 2023, with a year-on-year growth of 3.3%[35]. - E-commerce B2C sales in the pharmaceutical sector grew by 21.0%, significantly outpacing the growth of physical stores[35]. - The company ranked 8th in the "Top 50 Chain Pharmacies" in China for 2022-2023, reflecting its strong market position[36]. - The overall retail sales of consumer goods in China increased by 7.2% in 2023, indicating a positive market trend for the pharmaceutical retail sector[34]. - The company opened 1,881 new stores in 2023, bringing the total number of stores to 7,337, with 4,104 being directly operated stores[41]. Operational Efficiency and Strategy - The company has adopted a combined procurement model to enhance operational efficiency and meet regional demands[37]. - The company has implemented a digital transformation strategy, launching a new ERP system and a spatial data site selection platform, which has improved operational efficiency and new store expansion capabilities[57]. - The company aims to deepen its market presence in northern regions while maintaining a focus on the Shandong market, utilizing a combination of self-operated, franchised, and acquired stores for expansion[64]. - The company is adopting a "new store opening + acquisition + cooperation + franchising" strategy to accelerate store network expansion and strengthen market barriers in existing regions[124]. Investments and Acquisitions - The company has made significant investments in health equipment and rehabilitation products, targeting the aging population with tailored services[67]. - The company has acquired several pharmacy chains, including a 69% stake in Harbin Baofeng Pharmacy, to expand its market presence[75]. - The company completed significant equity investments totaling CNY 476,451,944.28 during the reporting period[99]. - The company has completed the acquisition of 90% control in Huai'an Xiansheng Pharmaceutical Management Co., Ltd. and 51% control in Gansu Shuyuan Baixing Pharmaceutical Chain Co., Ltd.[198]. Employee and Talent Management - The total number of employees at the end of the reporting period is 16,485, with 4,818 in the parent company and 11,667 in major subsidiaries[178]. - The company plans to implement an employee stock ownership plan to enhance the interest-sharing mechanism between workers and owners, improving governance and competitiveness[180]. - The company emphasizes a diversified incentive mechanism, including individual, team, and organizational incentives, to enhance talent value contribution[179]. - The company is committed to talent development through its training academy, which has nearly 500 instructors, ensuring a steady supply of qualified professionals to support its growth[127]. Risk Management and Governance - The company has set up a risk control center to enhance its comprehensive risk management system, focusing on identifying, measuring, monitoring, and addressing risks[121]. - The company is actively monitoring industry policy changes to adapt its business model and ensure compliance with regulations, thereby mitigating operational risks[123]. - The company has established a comprehensive internal management and control system, ensuring independence from controlling shareholders[147]. - The company has implemented a structured internal control framework to ensure compliance and operational efficiency[197]. Future Outlook - The company plans to focus on high-quality development in 2024, emphasizing customer value and digital transformation to improve operational efficiency[117]. - The strategy includes expanding through self-built stores, acquisitions, and partnerships, aiming for steady growth while deepening regional presence[117]. - The company aims to develop a comprehensive health ecosystem, leveraging its pharmaceutical retail business to create a leading smart health service platform[117]. - The company plans to enhance customer value by developing differentiated products and providing comprehensive health solutions, while actively managing membership services to identify growth opportunities[120].

漱玉平民大药房连锁股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 本人李相杰作为漱玉平民大药房连锁股份有限公司（以下简称"公司"） 独立董事，在 2023 年度严格按照《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司独立董事管理办法》《上市公司治理准则》等法律法 规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》（以下简称 "《公司章程》"）的规定和要求，认真、勤勉、独立的履行职责，积极出 席相关会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员 会委员的作用，切实维护了公司和全体股东的利益。现将本人 2023 年度履 行独立董事职责情况汇报如下： 一、基本情况 本人李相杰，中国籍，无境外居留权，1967 年生，硕士研究生学历，法学专 业。1993 年 3 月至 2000 年 2 月，任山东纵横家律师事务所合伙人；2000 年 3 月 至 2000 年 12 月，任北京广盛律师事务所专职律师；2001 年 1 月至 2008 年 10 月，任山东舜天律师事务所合伙人；2008 年 11 月至今，任山东誉实律师事务所 主任；2013 年 5 月至 2019 年 ...

漱玉平民大药房连锁股份有限公司 章 程 1 | | 录 | | --- | --- | | 目 | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 6 | | 第四章 | 股东和股东大会 7 | | 第一节 | 股东 7 | | 第二节 | 股东大会的一般规定 9 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会的提案与通知 14 | | 第五节 | 股东大会的召开 15 | | 第六节 | 股东大会的表决和决议 18 | | 第五章 | 董事会 22 | | 第一节 | 董事 22 | | 第二节 | 董事会 24 | | 第六章 | 总裁及其他高级管理人员 28 | | 第七章 | 监事会 30 | | 第一节 | 监事 30 | | 第二节 | 监事会 30 | | 第八章 | 财务会计制度、利润分配和审计 32 | | 第一节 | 财务会计制度 32 | | 第二节 | 内部审计 35 | | 第三 ...

Financial Performance - The company's revenue for Q1 2024 was ¥2,439,083,820.11, representing a 17.69% increase compared to ¥2,072,482,825.34 in the same period last year[4] - Net profit attributable to shareholders decreased by 83.72% to ¥10,508,208.55 from ¥64,553,649.73 year-on-year[4] - Basic and diluted earnings per share fell by 81.25% to ¥0.03, down from ¥0.16 in the same period last year[4] - The company achieved operating revenue of CNY 243.91 million in Q1 2024, representing a year-on-year increase of 17.69%[16] - The net profit attributable to shareholders decreased by 83.72% to CNY 10.51 million compared to the same period last year[16] - The net profit after deducting non-recurring gains and losses fell by 84.25% to CNY 9.51 million year-on-year[16] - Net profit for Q1 2024 was ¥11,377,582.93, a decrease of 82.9% from ¥66,526,141.25 in Q1 2023[30] - Earnings per share for Q1 2024 were ¥0.03, down from ¥0.16 in the same quarter last year[31] Cash Flow and Assets - The net cash flow from operating activities increased by 32.89% to ¥75,184,147.94, up from ¥56,575,234.08 in the previous year[4] - Cash received from operating activities totaled CNY 2,701,517,754.85, compared to CNY 2,216,545,326.15 in Q1 2023, reflecting a year-over-year increase of approximately 21.9%[34] - Total current assets amounted to approximately 5.71 billion CNY, an increase from 5.51 billion CNY at the beginning of the period[25] - Total assets reached approximately 9.56 billion CNY, up from 9.33 billion CNY at the beginning of the period[25] - Total cash and cash equivalents at the end of Q1 2024 amounted to CNY 946,508,791.12, up from CNY 1,021,875,903.46 at the end of Q1 2023[35] Liabilities and Equity - Total liabilities increased to ¥7,200,124,190.48 in Q1 2024 from ¥6,967,443,876.48 in Q1 2023[27] - Total equity attributable to shareholders of the parent company decreased to ¥2,268,028,613.50 from ¥2,292,063,021.84 year-over-year[27] - Minority interests increased to ¥96,617,961.98 in Q1 2024 from ¥74,169,508.13 in Q1 2023[27] - Long-term borrowings increased to approximately 749.83 million CNY from 658.18 million CNY[26] Operational Changes - The company plans to expand its logistics capabilities, which contributed to increased operational costs impacting net profit[9] - The company operates a total of 7,934 stores across several provinces, with 4,341 being direct-operated stores[17] - The company opened 22 new stores and closed 3 stores in Q1 2024, resulting in a net increase of 19 stores[18] - The company is focusing on a direct chain marketing model and steady expansion strategy in various provinces[17] Expenses and Margins - The gross margin decreased by 1.7 percentage points due to changes in healthcare policies affecting sales channels and product selection[16] - The company reported a significant increase in sales expenses, which rose to ¥523,927,303.51 from ¥424,345,254.99 in the previous year[30] - The company experienced a rise in management expenses, totaling ¥73,724,503.68 compared to ¥61,463,906.19 in the same period last year[30] Shareholder Actions - The top shareholder, Li Wenjie, holds 35.17% of the shares, with a total of 142,560,000 shares pledged[12] - The company plans to optimize product structure and enhance service quality to improve profitability amid market challenges[16] - The company has a total of 296,040,000 restricted shares, with specific release dates for certain shareholders[15] - The company approved a second batch of restricted stock grants on February 7, 2024, awarding 605,000 shares at a price of 8.675 CNY per share to 32 incentive recipients[19] - The company plans to repurchase shares with a total fund of no less than 40 million CNY and no more than 60 million CNY, with a maximum repurchase price of 18 CNY per share[20] - As of March 31, 2024, the company has repurchased a total of 2,602,588 shares, accounting for 0.64% of the total share capital, with a total transaction amount of approximately 38.12 million CNY[20] Investment Activities - Total cash inflow from investment activities was CNY 152,897,493.80, significantly higher than CNY 7,890,915.99 in the previous year[35] - The company reported a total cash outflow from investment activities of CNY 133,783,524.18, a decrease from CNY 270,591,408.28 in the previous year[35] - The company received CNY 3,150,000.00 from investments in Q1 2024, compared to CNY 1,664,000.00 in the previous year, indicating growth in investment activities[35] Debt and Financing - The company reported a significant increase in long-term payables by 4891.99% to ¥18,795,889.65, primarily due to financing leases[9] - The net cash flow from financing activities for Q1 2024 was CNY 22,304,637.52, compared to a negative cash flow of CNY -282,889,970.43 in Q1 2023, indicating a recovery in financing[35] - The cash flow from financing activities included CNY 358,540,000.00 received from borrowings, a significant increase from CNY 50,000,000.00 in Q1 2023[35] Inventory and Impairment - The company experienced a 327.50% increase in asset impairment losses, amounting to -¥7,969,615.48, due to increased inventory[9] - The company reported a significant increase in inventory, with current inventory valued at approximately 2.16 billion CNY, compared to 2.07 billion CNY at the beginning of the period[24]

漱玉平民大药房连锁股份有限公司 董事会薪酬与考核委员会制度 第一章 总 则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司治理准则》《漱玉平民大药房连锁股份有限公司 章程》（以下简称"《公司章程》"）及其他有关法律法规、规范性文件等规定， 公司董事会特设立薪酬与考核委员会（以下简称"委员会"），并制定本制度。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制定 公司董事及高级管理人员的考核标准并进行考核；负责制定、审查公司董事高级 管理人员的薪酬政策与方案，对董事会负责。 第三条 本制度所称董事是指在公司支取薪酬的董事长、董事（非独立董 事），高级管理人员是指董事会聘任的总裁、副总裁、财务总监、董事会秘书以 及由总裁提请董事会认定的其他高级管理人员。 第二章 人员组成 第四条 委员会成员由三名董事组成，其中两名由独立董事担任。 第五条 委员会由董事长、二分之一以上独立董事或者全体董事的三分之 一提名，并由董事会选举产生。 （二）制定或者变更股权激励计划、员工持股计划，激励对象 ...

东兴证券股份有限公司关于漱玉平民大药房连锁股份有限公 司 2023 年度募集资金存放与使用情况的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为漱玉平 民大药房连锁股份有限公司（以下简称"漱玉平民"或"公司"）持续督导阶段的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规 则》以及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关法律、法规和规范性文件的规定，对漱玉平民 2023 年度募集资金 存放与使用情况进行了专项核查，核查意见如下： 一、募集资金基本情况 （一）募集资金到位情况 1、首次公开发行股票 经中国证券监督管理委员会《关于同意漱玉平民大药房连锁股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]1808 号）同意注册，公司首次公开 发行人民币普通股（A 股）4,054.00 万股，每股面值人民币 1.00 元，每股发行价 格为人民币 8.86 元，发行募集资金总额为人民币 359,184,400.00 元，扣除发行费 用人民币 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2024-031 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于为全资及控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于2024年1月22日召开第三届 董事会第二十四次会议，于2024年2月7日召开2024年第一次临时股东大会，审议通过了《关 于2024年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同意公司 及子公司2024年度对合并报表范围内各级子公司提供的担保额度为人民币158,950.00万元， 其中公司向全资子公司漱玉医药物流（山东）有限公司（以下简称"山东物流"）提供不 超过68,000万元的担保额度，公司向持股51%的控股子公司漱玉医药物流（吉林）有限公司 （以下简称"吉林物流"）提供不超过6,120万元的担保额度。担保额度有效期自2024年第 一次临时股东大会审议通过之日 ...

关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2024-032 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 特别提示： 5、根据《漱玉平民大药房连锁股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）中相关约定："在本次发行的可转换公司债 券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价低于当 期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交公司股东大会表 决。" 截至本公告日，漱玉平民大药房连锁股份有限公司（以下简称"公司"）股票自 2024 年 4 月 12 日至 2024 年 4 月 25 日已有 10 个交易日的收盘价格低于当期转股价格的 85%（即 12.75 元/股）的情形，预计可能触发"漱玉转债"转股价格向下修正条件。若触发转股价 格修正条件，公司将按照 ...

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its future performance [66]. Core Insights - The retail pharmacy market in China is expected to grow significantly, driven by policy support, increasing chain concentration, and enhanced professional capabilities [14]. - The company is focusing on expanding its store network through a combination of self-built, acquired, and franchised stores, with a strong emphasis on the Shandong market and plans for national expansion [23][26]. - The retail pharmacy industry shows a low concentration of leading players, suggesting substantial growth potential for companies that can leverage scale advantages [7]. Summary by Sections Retail Pharmacy Market Overview - The retail pharmacy market in China has seen a steady increase in sales, with a compound annual growth rate (CAGR) of 8.2% from 2013 to 2022, growing from 255.8 billion to 520.9 billion [14]. - The chain rate of retail pharmacies varies significantly across regions, with Shanghai having the highest rate at 92.09%, compared to a national average of 57.76% [4][2]. Company Strategy and Expansion - As of Q3 2023, the company operates 6,778 stores, with 4,015 being self-operated and 2,763 franchised, primarily concentrated in Shandong [23][26]. - The company aims to enhance its market share in the Northeast region through acquisitions, capitalizing on the lower chain rates in that area [41][37]. Financial Projections - The company expects retail business revenue growth rates of 17.60%, 29.21%, and 25.12% for 2023, 2024, and 2025, respectively, with a stable gross margin of 31% [62]. - The projected total revenue for 2023 is 7.823 billion, with a year-on-year growth of 19% [64]. Online and Digital Strategy - The company has developed a robust online sales platform, achieving 5.8 billion in online revenue in H1 2023, a 61% increase year-on-year, accounting for 13.6% of total revenue [49]. - The integration of public and private domain marketing strategies has significantly enhanced customer engagement and sales performance [50]. Brand Development and Product Diversification - The company is actively developing its own product lines, including traditional Chinese medicine and health products, with a focus on appealing to a diverse customer base [58]. - The introduction of the "漱小玉" brand aims to enhance brand recognition and community engagement through various initiatives [54].

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2024-030 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2024 年 2 月 19 日召开第 三届董事会第二十六次会议及第三届监事会第十八次会议分别审议通过了《关于回购公司 股份方案的议案》，拟使用自有资金以集中竞价交易方式回购公司已发行的部分人民币普通 股（A 股）股票，用于维护公司价值及股东权益所必需；本次回购资金总额不低于人民币 4,000 万元（含）且不超过人民币 6,000 万元（含），回购价格不超过 18 元/股（含）。回购 股份的实施期限为自公司董事会审议通过回购股份方案之日起不超过 3 个月。具体内容详 见公司于 2024 年 2 月 20 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股 份方案的公告》。 公司回购股份的时间、 ...